Pacira Pharmaceuticals Inc. (NASDAQ:PCRX) Receives Consensus Recommendation of “Hold” from Brokerages
Shares of Pacira Pharmaceuticals Inc. (NASDAQ:PCRX) have been assigned a consensus rating of “Hold” from the fourteen brokerages that are presently covering the firm. Two analysts have rated the stock with a sell recommendation, four have assigned a hold recommendation and seven have given a buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $77.13.
Several research analysts recently weighed in on the company. Brean Capital assumed coverage on Pacira Pharmaceuticals in a research report on Friday. They issued a “hold” rating on the stock. Zacks Investment Research lowered Pacira Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 4th. Wedbush reaffirmed an “outperform” rating and issued a $109.00 target price on shares of Pacira Pharmaceuticals in a research report on Tuesday, September 27th. Jefferies Group reissued a “buy” rating and issued a $60.00 price objective (down from $74.00) on shares of Pacira Pharmaceuticals in a research report on Monday, September 26th. Finally, Cowen and Company reissued a “hold” rating on shares of Pacira Pharmaceuticals in a research report on Tuesday, September 20th.
Pacira Pharmaceuticals (NASDAQ:PCRX) traded up 1.01% during mid-day trading on Monday, reaching $35.01. The company had a trading volume of 597,469 shares. The company’s market capitalization is $1.31 billion. The firm’s 50 day moving average price is $38.81 and its 200-day moving average price is $44.13. Pacira Pharmaceuticals has a 12 month low of $31.08 and a 12 month high of $80.25.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/10/pacira-pharmaceuticals-inc-nasdaqpcrx-receives-consensus-recommendation-of-hold-from-brokerages.html
Pacira Pharmaceuticals (NASDAQ:PCRX) last issued its earnings results on Thursday, August 4th. The company reported $0.19 earnings per share for the quarter, topping the consensus estimate of $0.03 by $0.16. The business had revenue of $69.60 million for the quarter, compared to analyst estimates of $67.80 million. Pacira Pharmaceuticals had a positive return on equity of 0.02% and a negative net margin of 4.21%. The business’s quarterly revenue was up 17.8% on a year-over-year basis. During the same period last year, the company posted $0.20 EPS. Equities research analysts anticipate that Pacira Pharmaceuticals will post $0.44 earnings per share for the current year.
In related news, President James S. Scibetta sold 25,000 shares of Pacira Pharmaceuticals stock in a transaction dated Monday, August 15th. The stock was sold at an average price of $45.21, for a total value of $1,130,250.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO David M. Stack sold 15,000 shares of Pacira Pharmaceuticals stock in a transaction dated Monday, August 15th. The stock was sold at an average price of $45.32, for a total value of $679,800.00. The disclosure for this sale can be found here. 6.90% of the stock is owned by corporate insiders.
A number of institutional investors have recently bought and sold shares of PCRX. FMR LLC increased its position in Pacira Pharmaceuticals by 19.1% in the second quarter. FMR LLC now owns 5,567,088 shares of the company’s stock worth $187,778,000 after buying an additional 892,511 shares during the period. Vanguard Group Inc. increased its position in Pacira Pharmaceuticals by 2.6% in the second quarter. Vanguard Group Inc. now owns 2,587,221 shares of the company’s stock worth $87,268,000 after buying an additional 64,898 shares during the period. BlackRock Fund Advisors increased its position in Pacira Pharmaceuticals by 0.6% in the second quarter. BlackRock Fund Advisors now owns 1,591,688 shares of the company’s stock worth $53,688,000 after buying an additional 9,454 shares during the period. Westfield Capital Management Co. LP increased its position in Pacira Pharmaceuticals by 92.5% in the second quarter. Westfield Capital Management Co. LP now owns 1,333,868 shares of the company’s stock worth $44,991,000 after buying an additional 640,814 shares during the period. Finally, State Street Corp increased its position in Pacira Pharmaceuticals by 8.0% in the second quarter. State Street Corp now owns 1,197,912 shares of the company’s stock worth $40,406,000 after buying an additional 88,301 shares during the period.
About Pacira Pharmaceuticals
Pacira Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is focused on the development, commercialization and manufacture of pharmaceutical products, based on its DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control.
Receive News & Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.